Tim McCarthy, Chairman of ImmuPharma (IMM) discusses the deal with US-based Avion Pharmaceuticals, the agreement with Lanstead Capital and what the future holds for ImmuPharma regarding new trial design as well as anticipated upcoming milestones.
Mr. McCarthy said: “Avion have agreed to fully fund the phase 3 development through to registration and all the costs surrounding that up to $25 million. To put that in context, that's more than twice the amount we spent on the first phase 3 study”
Commenting on a new trial design he said: “What we are now doing is putting together a new design based on the lessons we learned from the first phase 3”
He said: “If we choose a particular profile of patients with a particular biomarker, then we will more than likely have a higher chance of success in terms of showing the efficacy.”
Follow News & Updates from ImmuPharma here: